The Viamet Group discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our promising clinical and preclinical candidates include potential therapies to treat invasive and hospital-based fungal infections, cancer, cardiovascular and orphan diseases. Focusing on the needs of patients and clinicians, and utilizing our proprietary MIDAS (Metalloenzyme Inhibitor Design And Synthesis) technology, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs.